v3.26.1

Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2026	Dec. 31, 2025
Current Assets:
Cash and cash equivalents	$ 2,950,877	$ 7,201,014
Deferred offering costs	27,248	45,486
Prepaid expenses and other current assets	1,100,214	856,301
Total current assets	4,078,339	8,102,801
Noncurrent Assets:
Prepaid expenses, net of current portion	552,839	502,962
Property and equipment, net	22,014	17,703
Total noncurrent assets	574,853	520,665
Total Assets	4,653,192	8,623,466
Current Liabilities:
Accounts payable and accrued expenses	4,350,134	3,772,339
Notes payable	232,353	328,571
Total current liabilities	4,582,487	4,100,910
Total Liabilities	4,582,487	4,100,910
Commitments and contingencies
Stockholders' Equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized and 0 shares issued and outstanding	0	0
Common stock, $0.001 par value, 300,000,000 shares authorized and 811,449 and 632,516 shares issued and outstanding, respectively	811	633
Additional paid-in capital	105,282,208	104,797,191
Accumulated deficit	(105,212,314)	(100,275,268)
Total Stockholders' Equity	70,705	4,522,556
Total Liabilities and Stockholders' Equity	$ 4,653,192	$ 8,623,466

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.

CNS Pharmaceuticals, Inc. 10-Q